Literature DB >> 6637763

Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.

J H McKillop, M R Bristow, M L Goris, M E Billingham, K Bockemuehl.   

Abstract

We examined radionuclide-determined left ventricular ejection fractions (LVEF) at rest and during graded exercise in 37 patients receiving doxorubicin (Adriamycin) therapy in whom the risk of developing congestive heart failure (CHF) was precisely defined by endomyocardial biopsy and right heart catheterization. Echocardiographic (Echo %FS) and phonocardiographic (PEP/LVET) measurements of LV function were also determined. An abnormal LVEF at rest (less than or equal to 45%) had a sensitivity of 53% and a specificity of 75% for detecting patients at moderate or high risk of developing CHF. The addition of exercise LVEF increased the sensitivity of detection of moderate or high-risk patients to 89% but lowered the specificity to 41%. Exercise LVEF improved the sensitivity of detection of high-risk patients from 58% to 100%. Echo %FS and PEP/LVET yielded lower sensitivities than rest or exercise LVEF. As a single test, exercise LVEF possesses the sensitivity for use as a screening method for anthracycline cardiotoxicity, but the lack of specificity prevents the use of single values as a definitive test. Single rest LVEF determinations, although more specific than exercise LVEF, do not possess the sensitivity for use as screening or definitive tests.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637763     DOI: 10.1016/0002-8703(83)90651-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  32 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).

Authors:  W Stöhr; M Paulides; I Brecht; A Kremers; J Treuner; T Langer; J D Beck
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-05       Impact factor: 4.553

Review 3.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

4.  Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.

Authors:  H Havsteen; I Brynjolf; T Svahn; P Dombernowsky; J Godtfredsen; O Munck
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Noninvasive imaging of cardiovascular injury related to the treatment of cancer.

Authors:  Suwat Kongbundansuk; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2014-08

Review 6.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

7.  Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables.

Authors:  G Tjeerdsma; M T Meinardi; W T van Der Graaf; M P van Den Berg; N H Mulder; H J Crijns; E G de Vries; D J van Veldhuisen
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

8.  Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.

Authors:  Timothy C Tan; Marielle Scherrer-Crosbie
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-12-01

Review 9.  Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure.

Authors:  Vinisha Garg; Gabriel Vorobiof
Journal:  Curr Oncol Rep       Date:  2016-08       Impact factor: 5.075

10.  Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI.

Authors:  D Piwnica-Worms; M L Chiu; J F Kronauge
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.